177 related articles for article (PubMed ID: 6707919)
21. Stereoselectivity of S- and R-sulpiride for pre- and postsynaptic dopamine receptors in the canine kidney.
Bass AS; Robie NW
J Pharmacol Exp Ther; 1984 Apr; 229(1):67-71. PubMed ID: 6707948
[TBL] [Abstract][Full Text] [Related]
22. Blood pressure lowering effects of N,N-di-n-propyl-dopamine in rats: evidence for stimulation of peripheral dopamine receptors leading to inhibition of sympathetic vascular tone.
Cavero I; Lefèvre-Borg F; Gomeni R
J Pharmacol Exp Ther; 1981 Aug; 218(2):515-24. PubMed ID: 7252851
[TBL] [Abstract][Full Text] [Related]
23. Effect of bromocriptine on neurogenic vasoconstriction in the isolated autoperfused hindquarters of the rat.
Roquebert J; Alaoui K; Morán A
Fundam Clin Pharmacol; 1990; 4(5):539-45. PubMed ID: 2289745
[TBL] [Abstract][Full Text] [Related]
24. Non-adrenergic, non-cholinergic vascular control with reference to neuropeptide Y, vasoactive intestinal polypeptide and nitric oxide.
Modin A
Acta Physiol Scand Suppl; 1994; 622():1-74. PubMed ID: 7524267
[TBL] [Abstract][Full Text] [Related]
25. Renal hemodynamics in hemorrhagic hypotension: studies on the effects of pre- and postjunctional dopamine receptor agonists.
Hamed AT; Ginos JZ; Ekas RD; Jandhyala BS; Lokhandwala MF
J Cardiovasc Pharmacol; 1983; 5(2):207-12. PubMed ID: 6188891
[TBL] [Abstract][Full Text] [Related]
26. Modification of the cardiovascular effects of L-dopa by decarboxylase inhibitors.
Watanabe AM; Parks LC; Kopin IJ
J Clin Invest; 1971 Jun; 50(6):1322-8. PubMed ID: 5578236
[TBL] [Abstract][Full Text] [Related]
27. The role of central dopamine (DA) receptors in the regulation of blood pressure.
Jaszlits L; Tardos L; Borsy J
Pol J Pharmacol Pharm; 1985; 37(3):405-10. PubMed ID: 4070082
[TBL] [Abstract][Full Text] [Related]
28. The role of sympathetic nervous system in the vascular actions of dopamine.
Lokhandwala MF; Jandhyala BS
J Pharmacol Exp Ther; 1979 Jul; 210(1):120-6. PubMed ID: 36477
[No Abstract] [Full Text] [Related]
29. Dopamine-induced neurogenic vaso-dilatation in the intact hindleg of the dog.
Bogaert MG; Schaepdryver AF; Willems JL
Br J Pharmacol; 1977 Feb; 59(2):283-92. PubMed ID: 189872
[TBL] [Abstract][Full Text] [Related]
30. Vasodilatation produced by apomorphine in the hindleg of the dog.
Buylaert WA; Willems JL; Bogaert MG
J Pharmacol Exp Ther; 1977 Jun; 201(3):738-46. PubMed ID: 864606
[TBL] [Abstract][Full Text] [Related]
31. [Effect of pergolide on the kinetics of the dopamine receptors in the corpus striatum of the rat].
Jiang DH
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):209-13. PubMed ID: 4075909
[No Abstract] [Full Text] [Related]
32. Intracisternal administration of pergolide, a dopamine receptor agonist, triggers the release of an inhibitor of ouabain-sensitive sodium, potassium-dependent adenosine triphosphatase and enhances vascular reactivity in anaesthetized dogs.
Jandhyala BS; Lokhandwala MF; Kivlighn SD; Ansari AF; De Feo ML
Clin Sci (Lond); 1987 Aug; 73(2):183-8. PubMed ID: 2443297
[TBL] [Abstract][Full Text] [Related]
33. Lack of dilator effect of leptin in the hindlimb vascular bed of conscious rats.
Rahmouni K; Jalali A; Morgan DA; Haynes WG
Eur J Pharmacol; 2005 Aug; 518(2-3):175-81. PubMed ID: 16054621
[TBL] [Abstract][Full Text] [Related]
34. Vasodilator and vasoconstrictor responses induced by 5-hydroxytryptamine in the in situ blood autoperfused hindquarters of the anaesthetized rat.
Calama E; Fernández MM; Morán A; Martín ML; San Román L
Naunyn Schmiedebergs Arch Pharmacol; 2002 Aug; 366(2):110-6. PubMed ID: 12122496
[TBL] [Abstract][Full Text] [Related]
35. Degree of selectivity of pergolide as an agonist at presynaptic versus postsynaptic dopamine receptors: implications for prevention or treatment of tardive dyskinesia.
Fuller RW; Clemens JA; Hynes MD
J Clin Psychopharmacol; 1982 Dec; 2(6):371-5. PubMed ID: 7174859
[TBL] [Abstract][Full Text] [Related]
36. Central dopamine receptors mediating pergolide-induced elevation of serum corticosterone in rats. Characterization by the use of antagonists.
Fuller RW; Snoddy HD
Neuropharmacology; 1984 Dec; 23(12A):1389-94. PubMed ID: 6527743
[TBL] [Abstract][Full Text] [Related]
37. Antihypertensive effects of mesulergine: further evidence for a peripheral site of action of dopamine agonists.
Begaud B; Dang Tran L; Montastruc JL; Montastruc P
Fundam Clin Pharmacol; 1987; 1(3):153-9. PubMed ID: 3428838
[TBL] [Abstract][Full Text] [Related]
38. Local and neurally mediated effects of sufentanil on canine skeletal muscle vascular resistance.
O'Keefe RJ; Domalik-Wawrzynski L; Guerrero JL; Rosow CE; Lowenstein E; Powell WJ
J Pharmacol Exp Ther; 1987 Aug; 242(2):699-706. PubMed ID: 2886649
[TBL] [Abstract][Full Text] [Related]
39. Effect of dopamine and apomorphine on bone circulation.
Tran MA
J Pharmacol; 1981; 12(4):417-26. PubMed ID: 7321571
[TBL] [Abstract][Full Text] [Related]
40. Ganglionic dopamine receptors as mediators of the inhibition of neurogenic vasoconstriction produced by fenoldopam.
Lokhandwala MF; Sabouni MH
J Auton Pharmacol; 1985 Dec; 5(4):301-5. PubMed ID: 2869042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
